NASDAQ:EVGN - Evogene Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$3.08 +0.03 (+0.98 %)
(As of 06/24/2018 04:54 AM ET)
Previous Close$3.08
Today's Range$3.0301 - $3.08
52-Week Range$2.66 - $5.74
Volume1,693 shs
Average Volume19,909 shs
Market Capitalization$78.55 million
P/E RatioN/A
Dividend YieldN/A
Beta0.76
Evogene logoEvogene Ltd., a biotechnology company, focuses on the enhancement of crop productivity and performance in the United States and Germany. It operates through two segments, Evogene and Evofuel. The Evogene segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. This segment develops seed traits enhancing plant yield and tolerance to abiotic stresses, such as enhanced tolerance to drought, heat, and salinity, as well as seed traits for enhancing plant resistance to biotic stresses, including resistance to diseases, pests, and insects; novel herbicides; and bio-stimulants, which include microbial-based products that are applied externally to the plant for yield enhancement. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Evofuel segment develops enhanced species of the castor bean plant to serve as a source of feedstock for biofuel and other industrial uses. The company has strategic collaborations with various agricultural companies, including BASF, Bayer, DuPont, Monsanto, and Syngenta that cover 24 products in various stages of development. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

Receive EVGN News and Ratings via Email

Sign-up to receive the latest news and ratings for EVGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Agricultural chemicals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EVGN
CUSIPN/A
Phone972-8931-1900

Debt

Debt-to-Equity RatioN/A
Current Ratio14.55
Quick Ratio14.55

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.38 million
Price / Sales23.46
Cash FlowN/A
Price / CashN/A
Book Value$2.69 per share
Price / Book1.14

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-20,830,000.00
Net Margins-706.44%
Return on Equity-29.69%
Return on Assets-26.71%

Miscellaneous

Employees240
Outstanding Shares25,750,000

The Truth About Cryptocurrencies

Evogene (NASDAQ:EVGN) Frequently Asked Questions

What is Evogene's stock symbol?

Evogene trades on the NASDAQ under the ticker symbol "EVGN."

How were Evogene's earnings last quarter?

Evogene Ltd (NASDAQ:EVGN) issued its quarterly earnings data on Tuesday, May, 29th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by $0.02. The biotechnology company had revenue of $0.37 million for the quarter. Evogene had a negative return on equity of 29.69% and a negative net margin of 706.44%. View Evogene's Earnings History.

When is Evogene's next earnings date?

Evogene is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for Evogene.

Who are some of Evogene's key competitors?

Who are Evogene's key executives?

Evogene's management team includes the folowing people:
  • Mr. Ofer Haviv CPA, CEO & Pres (Age 52)
  • Mr. Ido Dor, Exec. VP & GM of Ag-Biologicals (Age 42)
  • Mr. Eran Kosover, Exec. VP & GM of Ag-Chemicals (Age 41)
  • Mr. Alex Taskar, Chief Financial Officer (Age 52)
  • Dr. Hagai Karchi, Chief Technology Officer (Age 56)

Has Evogene been receiving favorable news coverage?

Headlines about EVGN stock have trended somewhat positive recently, Accern reports. The research firm scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Evogene earned a media sentiment score of 0.09 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 45.67 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are Evogene's major shareholders?

Evogene's stock is owned by many different of retail and institutional investors. Top institutional investors include ETF Managers Group LLC (0.14%). View Institutional Ownership Trends for Evogene.

Which major investors are buying Evogene stock?

EVGN stock was bought by a variety of institutional investors in the last quarter, including ETF Managers Group LLC. View Insider Buying and Selling for Evogene.

How do I buy shares of Evogene?

Shares of EVGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Evogene's stock price today?

One share of EVGN stock can currently be purchased for approximately $3.08.

How big of a company is Evogene?

Evogene has a market capitalization of $78.55 million and generates $3.38 million in revenue each year. Evogene employs 240 workers across the globe.

How can I contact Evogene?

Evogene's mailing address is 13 GAD FEINSTEIN STREET, REHOVOT L3, 7612002. The biotechnology company can be reached via phone at 972-8931-1900 or via email at [email protected]


MarketBeat Community Rating for Evogene (EVGN)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  84 (Vote Outperform)
Underperform Votes:  89 (Vote Underperform)
Total Votes:  173
MarketBeat's community ratings are surveys of what our community members think about Evogene and other stocks. Vote "Outperform" if you believe EVGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.